Our manufacturing sites
Located across Europe, the US and Asia, our cGMP-compliant facilities have the people and technology to create high-end solutions efficiently and at scale.
Contract manufacturing news
Fierce Biotech Interviews Anton Gerdenitsch, Global Head of Contract Manufacturing
August 28, 2023
Exclusive interview with Anton Gerdenitsch, discussing the increasing demand for emerging technologies and the challenges companies face in bringing their innovation to market.
Gain exclusive insights on the strategic approach of Novartis GBTC to provide an unmatched experience as a CDMO partner supported by a robust global technology network.
August 27, 2023
¡Buenos días! We are excited to be exhibiting in CPHI Barcelona from October 24th to 26th, an event that will connect thousands of pharma industry leaders. Visit us at booth #3F68 to expand your network with great business opportunities and be inspired by emerging innovations. Looking forward to meeting you there!
July 10, 2023
At Novartis’ Global Biotech Cooperations, we are a trusted partner in manufacturing high-quality medicines at competitive pricing. Watch Harald Oberegger PhD explain how we can bring your drug to market quicker with help from Novartis’ extensive knowledge and long-standing experience.
June 16, 2023
At Novartis Global Biotech Cooperations, we have a unique and large global manufacturing network, offering a truly end-to-end service. We started contract manufacturing 20 years ago in microbial manufacturing, and have since expanded into various technologies like mammalian cells, cell and gene therapy, and others. Check out the full interview below.
April 13, 2023
We're thrilled to have hosted our latest webinar on 13th April “past, present, and future of Novartis' Global Biotech Cooperations Cell and Gene Therapy”. We were fortunate to have an exceptional lineup of speakers. The recording of the session can be found in the link below. We can't wait to bring you more exciting topics in our upcoming webinars.
February 6, 2023
Global Biotech Corporations, the contract manufacturing hub of Novartis is excited to share that we are expanding our portfolio of services by entering into a collaboration with Navigate BioPharma Services Inc, an independently operating subsidiary within the Novartis Group of Companies, to offer innovative solutions and service offerings in the Cell and Gene space.
Global Biotech Cooperations has already established itself as a trusted partner through its manufacturing capabilities and supply chain footprint and the collaboration with Navigate is a significant step towards scaling up and meeting patient needs. Navigate extensively worked towards the development and launch of the world’s first CAR-T therapy and by joining forces with Global Biotech Cooperation also has the potential to offer development process services in the Cell and Gene area.
This is an exciting time for both organizations and we look forward to providing our unique end-to-end services and products to our customers.
Watch the first edition of our webinar series as we discuss the journey of how Novartis GBTC has evolved into a Global Contract Manufacturing Organization over the last 40 years.
The facility will focus on Lenti and Adenoviral vectors, mainly for the contract manufacturing business. The new plant will be located at our Mengeš site in Slovenia and will become operational in early 2024. With this investment, we are addressing the worldwide growth in cell & gene therapies and increasing demand for capacity, driven by the global cell & gene therapy pipeline.
Basel, August 25, 2022 — Novartis today announced its intention to separate Sandoz, its generics and biosimilars division into a new publicly traded standalone company, by way of a 100% spin-off.
Basel, March 10, 2022 — Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.
Basel, October 21, 2021 — Novartis announced today that it has signed an initial agreement to leverage its manufacturing capacity and capabilities to address the COVID-19 pandemic by expanding its support of the fill and finish of the Pfizer-BioNTech COVID-19 vaccine. Novartis will use its sterile manufacturing facilities at its Novartis Technical Operations site in Ljubljana, Slovenia, to fill at least 24 million doses in 2022.
We’re Novartis Contract Manufacturing Organization that helps customers around the world produce and manufacture life-changing biotechnological products.